Author

Tyler J. Umansky

University of California San Diego

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioinformatics· 3 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 5 Approach:deep learning· 3 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Approach:graph neural network· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1 Research Focus:sequence-to-function modeling· 1

Frequent Co-Authors

Daniel J. HadersiD· 5 shared Sean M. Russell· 5 shared Virgil L. WoodsiD· 5 shared Davey Mitchell SmithiD· 3 shared Philippe A. GallayiD· 2 shared Adolfo García‐SastreiD· 1 shared Asha Z. GoodmaniD· 1 shared Briana Lynn McGoverniD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBioinformatics

Daniel J. HadersORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

MDL-001: an Oral, Direct-Acting Broad-Spectrum Antiviral for Influenza-Like Illness (ILI) and Chronic Hepatitis In Vivo

Virgil L. Woods, Tyler J. Umansky, Sean M. Russell, Asha Z. Goodman, Michael D. Bobardt, Briana Lynn McGovern, Romel Rosales, M. Luis Rodriguez, Harm van Bakel, Emilia Mia Sordillo, Viviana R. Simon, Adolfo García‐Sastre, Kris M. White, Philippe A. Gallay, Davey Smith, Daniel J. Haders

This paper evaluates MDL-001, a broad-spectrum antiviral, showing potent in vitro and in vivo activity against influenza, RSV, SARS-CoV-2, and hepatitis B/C/D viruses, with improved efficacy compared to existing treatments.

Pharmaceuticals · Oct 18, 2026Peer-reviewedPharmacology & Toxicology

AmesNet: A Task-Conditioned Deep Learning Model with Enhanced Sensitivity and Generalization in Ames Mutagenicity Prediction

Tyler J. Umansky, Virgil A. Woods, Sean M. Russell, Daniel J. Haders

AmesNet improves mutagenicity prediction by enhancing sensitivity without sacrificing balanced accuracy in novel chemical spaces.

Chemical Research in Toxicology · Jun 29, 2026Peer-reviewedPharmacology & Toxicology

GALILEO Generatively Expands Chemical Space and Achieves One-Shot Identification of a Library of Novel, Specific, Next Generation Broad-Spectrum Antiviral Compounds at High Hit Rates

Tyler J. Umansky, Virgil L. Woods, Sean M. Russell, David S. Garvey, Davey Mitchell Smith, Daniel J. Haders

This study uses GALILEO and ChemPrint to generate novel antiviral compounds targeting the conserved Thumb-1 site, achieving 100% hit rate in vitro against HCV and Coronavirus 229E.

bioRxiv · Jan 17, 2025 · PreprintBioinformatics

The RdRp Thumb-1 Pocket is a Conserved Target for Broad-Spectrum Antiviral Development

Virgil L. Woods, Tyler J. Umansky, Sean M. Russell, Philippe A. Gallay, Davey Mitchell Smith, Daniel J. Haders

The paper identifies the RdRp Thumb-1 pocket as a conserved target for broad-spectrum antivirals, validated through structural and biochemical analyses of multiple viruses.

bioRxiv · Mar 29, 2024 · PreprintBioinformatics

ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery

Tyler J. Umansky, Virgil A. Woods, Sean M. Russell, Davey Mitchell Smith, Daniel J. Haders

ChemPrint improves drug discovery by enhancing hit rates and chemical novelty through a novel AI framework, achieving higher performance on challenging targets.

bioRxiv · Mar 22, 2024 · PreprintBioinformatics